肾癌免疫治疗的研究进展

被引:5
作者
陈旭
李伟
机构
[1] 昆明理工大学附属医院泌尿外科
关键词
肾癌; 免疫治疗靶点; PD-1/PD-L1; 联合治疗; 生物标志物;
D O I
10.13488/j.smhx.20180315
中图分类号
R737.11 [肾、肾盂肿瘤];
学科分类号
100214 [肿瘤学];
摘要
肾癌起源于肾小管上皮,恶性程度很高,患者就诊时大多已经发生转移。虽然VEGF和m TOR为主的靶向治疗大大改善了肾癌的治疗现状,但患者最终会出现耐药。幸运的是肾癌具有潜在的免疫原性,PD-1/PD-L1抑制剂、个体化疫苗和CAR-T疗法等免疫疗法显示了巨大的临床效益。而且PD-1/PD-L1抑制剂与抑制血管生成或CDK4/6抑制剂等药物联合使用可以发挥出更强的治疗效果。在肾细胞癌中针对免疫治疗靶点和肿瘤生物学的进一步研究有望提供更有效的治疗手段,改善患者预后。然而这些新的免疫疗法发挥作用的同时,随之也会带来很多毒副作用。因此探索预测治疗反应的生物标志物十分重要,可以帮助确定哪些肾细胞癌患者适合这类治疗,提高治疗效应并使毒副作用降到最低。本文就肾癌中新的免疫治疗通过不同的分子机制抑制肾癌的发展和用于治疗的靶点而展开综述。
引用
收藏
页码:438 / 444
页数:7
相关论文
共 11 条
[1]
Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy [J].
Aparicio, L. M. A. ;
Fernandez, I. P. ;
Cassinello, J. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (10) :1175-1182
[2]
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy [J].
Kammerer-Jacquet, Solene-Florence ;
Medane, Sarah ;
Bensalah, Karim ;
Bernhard, Jean-Christophe ;
Yacoub, Mokrane ;
Dupuis, Frantz ;
Ravaud, Alain ;
Verhoest, Gregory ;
Mathieu, Romain ;
Peyronnet, Benoit ;
Brunot, Angelique ;
Laguerre, Brigitte ;
Lespagnol, Alexandra ;
Mosser, Jean ;
Dugay, Frederic ;
Belaud-Rotureau, Marc-Antoine ;
Rioux-Leclercq, Nathalie .
TARGETED ONCOLOGY, 2017, 12 (04) :487-494
[3]
An Overview of Emerging Immunotargets of Genitourinary Tumors [J].
Montironi, Rodolfo ;
Santoni, Matteo ;
Cheng, Liang ;
Lopez-Beltran, Antonio ;
Massari, Francesco ;
Matrana, Marc R. ;
Moch, Holger ;
Scarpelli, Marina .
CURRENT DRUG TARGETS, 2016, 17 (07) :750-756
[4]
Renal Cell Carcinoma Programmed Death-ligand 1; a New Direct Target of Hypoxia-inducible Factor-2 Alpha; is Regulated by von Hippel–Lindau Gene Mutation Status.[J].Yosra Messai;Sophie Gad;Muhammad Zaeem Noman;Gwenael Le Teuff;Sophie Couve;Bassam Janji;Solenne Florence Kammerer;Nathalie Rioux-Leclerc;Meriem Hasmim;Sophie Ferlicot;Véronique Baud;Arnaud Mejean;David Robert Mole;Stéphane Richard;Alexander M.M. Eggermont;Laurence Albiges;Fathia Mami-Chouaib;Bernard Escudier;Salem Chouaib.European Uro
[5]
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma [J].
Callea, Marcella ;
Albiges, Laurence ;
Gupta, Mamta ;
Cheng, Su-Chun ;
Genega, Elizabeth M. ;
Fay, Andre P. ;
Song, Jiaxi ;
Carvo, Ingrid ;
Bhatt, Rupal S. ;
Atkins, Michael B. ;
Hodi, F. Stephen ;
Choueiri, Toni K. ;
McDermott, David F. ;
Freeman, Gordon J. ;
Signoretti, Sabina .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) :1158-1164
[6]
Personalized approaches to active immunotherapy in cancer [J].
Ophir, Eran ;
Bobisse, Sara ;
Coukos, George ;
Harari, Alexandre ;
Kandalaft, Lana E. .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2016, 1865 (01) :72-82
[7]
Regression of Metastatic Clear Cell Kidney Cancer With Interleukin-2 Treatment Following Nivolumab (Anti-PD-1) Treatment [J].
Brayer, Jason ;
Fishman, Mayer .
JOURNAL OF IMMUNOTHERAPY, 2014, 37 (03) :187-191
[8]
Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides [J].
Kawashima, Hidenori ;
Obayashi, Aiko ;
Kawamura, Marie ;
Masaki, Sakae ;
Tamada, Satoshi ;
Iguchi, Taro ;
Uchida, Junji ;
Kuratsukuri, Katsuyuki ;
Tanaka, Tomoaki ;
Nakatani, Tatsuya .
BJU INTERNATIONAL, 2014, 113 (02) :320-332
[9]
Chemotherapy in metastatic renal cell carcinoma today? A systematic review [J].
Buti, Sebastiano ;
Bersanelli, Melissa ;
Sikokis, Angelica ;
Maines, Francesca ;
Facchinetti, Francesco ;
Bria, Emilio ;
Ardizzoni, Andrea ;
Tortora, Giampaolo ;
Massari, Francesco .
ANTI-CANCER DRUGS, 2013, 24 (06) :535-554
[10]
Systemic Therapy in Metastatic Renal Cell Carcinoma.[J].S. O. Pyrhönen.Scandinavian Journal of Surgery.2004, 2